VIVOのチャート
VIVOの企業情報
symbol | VIVO |
---|---|
会社名 | Meridian Bioscience Inc. (メリディアン・バイオサイエンス) |
分野(sector) | Health Care ヘルスケア |
産業(industry) | Biotechnology: In Vitro_In Vivo Diagnostic Substances |
業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連(Health Care) |
概要 | 事業概要 メリディアン・バイオサイエンス(Meridian Bioscience Inc.)は胃腸、呼吸器、ウイルス、寄生虫感染症、血液鉛濃度の上昇を対象とした診断検査キットの開発・製造・販売、研究者と他の診断メーカーが使用するバルク抗原、抗体、ポリメラーゼ連鎖反応(PCR)・定量PCR(qPCR)試薬、ヌクレオチド、コンピテントセルおよびバイオリサーチ試薬の製造・販売に従事するライフサイエンス会社である。同社のセグメントには、診断およびライフサイエンスが含まれる。診断セグメントにはシンシナティにおいて製造事業、北米、中南米、ヨーロッパ、中東およびアフリカ(EMEA)および米州およびEMEA外の他の国々などにおいて診断テストキットの販売と流通を行う。ライフサイエンス事業はテネシー州メンフィス、フロリダ州ボカラトン、イギリスのロンドン、ドイツのルッケンヴァルデ、オーストラリアのシドニーにある製造事業を行う。 メリディアン・バイオサイエンスは、米国のライフサイエンス事業会社。おもに胃腸、ウイルス、呼吸器、寄生虫感染症などの診断検査キットの開発、製造、販売を行う。バルク抗原、抗体、PCR/qPCR試薬、ヌクレオチド、コンピテント細胞、バイオ研究用試薬の製造、販売のほか、新薬・ワクチン研究用に、タンパク質と生物学的製剤の受託開発・製造を手掛ける。 Meridian Bioscience Inc. is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.The company is dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, Meridian provides critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, Meridian provides diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. The company builds relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world. |
本社所在地 | 3471 River Hills Drive Cincinnati OH 45244 USA |
代表者氏名 | David C. Phillips デビッド・C.フィリップス |
代表者役職名 | Chairman of the Board 取締役会会長 |
電話番号 | +1 513-271-3700 |
設立年月日 | 27912 |
市場名 | NASDAQ National Market System |
ipoyear | 1986年 |
従業員数 | 640人 |
url | www.meridianbioscience.com |
nasdaq_url | https://www.nasdaq.com/symbol/vivo |
adr_tso | ― |
EBITDA | EBITDA(百万ドル) 44.73600 |
終値(lastsale) | 14.67 |
時価総額(marketcap) | 621939373.74 |
時価総額 | 時価総額(百万ドル) 660.09520 |
売上高 | 売上高(百万ドル) 210.16800 |
企業価値(EV) | 企業価値(EV)(百万ドル) 653.46220 |
当期純利益 | 当期純利益(百万ドル) 22.64800 |
決算概要 | 決算概要 BRIEF: For the nine months ended 30 June 2018 Meridian Bioscience Inc. revenues increased 6% to $160.5M. Net income before extraordinary items increased 7% to $16.9M. Revenues reflect US Diagnostics segment increase of 6% to $113.6M Life Sciences segment increase of 8% to $46.8M. Net income benefited from US Diagnostics segment income increase of 25% to $21.4M. Dividend per share decreased from $0.45 to $0.38. |
VIVOのテクニカル分析
VIVOのニュース
Latin American Dedicated Internet Access (DIA) Services Market Report 2022: Developing and/or Strengthening Telcos'' Managed Services Portfolio to present Future Opportunities - ResearchAndMarkets.com 2022/12/19 10:34:00 Kwhen Finance
Meridian Biosciences Stock: Why I Moved On But May Go Back In (NASDAQ:VIVO) 2022/12/13 19:53:57 Seeking Alpha
Meridian Biosciences released an update saying it set the closing date for its merger on Jan. 31. Read more on this deal and implications for investors.
Meridian Bioscience stock gains after announcing Jan. 31 closing date for sale 2022/12/12 15:54:02 Seeking Alpha
Meridian Bioscience (VIVO) rose 8% after it said its planned sale to SD Biosensor, SJL Partners is expected to close on Jan
Meridian Bioscience Fiscal Q4 Revenues Fall 14 Percent, Full-Year Revenues Grow 5 Percent 2022/11/22 15:14:01 GenomeWeb
The firm''s diagnostics segment revenues climbed 14 percent year over year in fiscal Q4, while life sciences revenues were down 37 percent.
Meridian Bioscience Non-GAAP EPS of $0.21, revenue of $65.67M 2022/11/22 13:46:35 Seeking Alpha
Meridian Bioscience press release (VIVO): Q4 Non-GAAP EPS of $0.21.Revenue of $65.67M (-13.8% Y/Y).Diagnostics segment net revenues increased 14% year-over-year to $39.2…
Looking Into Meridian Bioscience''s Return On Capital Employed 2022/08/26 14:33:47 Benzinga
Meridian Bioscience (NASDAQ: VIVO ) brought in sales totaling $67.77 million during Q3 according to data provided by Benzinga Pro . However, earnings decreased 125.52%, resulting in a loss of $7.34 million. In Q2, Meridian Bioscience earned $28.75 million and total sales reached $111.23 million. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign … Full story available on Benzinga.com
Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M (NASDAQ:VIVO) 2022/08/05 12:47:57 Seeking Alpha
Meridian Bioscience press release (VIVO): Q3 Non-GAAP EPS of $0.16 misses by $0.01.Revenue of $67.8M (+6.8% Y/Y) beats by $1M.Due to the pending transaction, Meridian will no…
Meridian Bioscience: Q3 Earnings Insights 2022/08/05 12:30:51 Benzinga
Meridian Bioscience (NASDAQ: VIVO ) reported its Q3 earnings results on Friday, August 5, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Meridian Bioscience reported in-line EPS of $0.16 versus an estimate of $0.16. Revenue … Full story available on Benzinga.com
Meridian Bioscience Misses Q3 EPS by 1c By Investing.com 2022/08/05 12:15:01 Investing.com
Meridian Bioscience Misses Q3 EPS by 1c
MERIDIAN BIOSCIENCE REPORTS THIRD QUARTER FISCAL 2022 OPERATING RESULTS 2022/08/05 12:00:00 PR Newswire
CINCINNATI, Aug. 5, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter ended June 30, 2022. Third Quarter Fiscal 2022 Highlights (Comparison to Third Quarter Fiscal 2021): Consolidated net revenues totaled $67.8 million,…
Meridian Bioscience rises 5% on boosted fiscal 2022 guidance 2022/02/04 17:13:47 Seeking Alpha
Meridian Bioscience <> rose following its Q1 results and a raised fiscal 2022 guidance.The company said net revenues in Q1 fiscal were $88.3M, only 5% below the record $92.9M in
Meridian Bioscience Q1 2022 Earnings Preview 2022/02/03 18:20:27 Seeking Alpha
Meridian Bioscience (NASDAQ:VIVO) is scheduled to announce Q1 earnings results on Friday, February 4th, before market open.The consensus EPS Estimate is $0.27 (-52.6% Y/Y) and the